Scarica l'app Stockscreener
31.57
13.24%
3.69
Precedente Chiudi:
$27.88
Aprire:
$29.71
Volume 24 ore:
1.36M
Relative Volume:
2.71
Capitalizzazione di mercato:
$995.22M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+82.38%
1M Prestazione:
+50.76%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$29.10
$32.98
Intervallo di 1 settimana:
$15.97
$33.20
Portata 52W:
$13.88
$33.20
Evommune Inc Stock (EVMN) Company Profile
Nome
Evommune Inc
Settore
Industria
Telefono
(650) 223-7745
Indirizzo
1841 PAGE MILL RD, PALO ALTO
Compare EVMN vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EVMN
Evommune Inc
|
31.57 | 878.89M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Evommune Inc Stock (EVMN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-22 | Iniziato | Oppenheimer | Outperform |
| 2026-01-08 | Iniziato | Raymond James | Strong Buy |
| 2026-01-06 | Iniziato | H.C. Wainwright | Buy |
| 2025-12-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-12-01 | Iniziato | Evercore ISI | Outperform |
| 2025-12-01 | Iniziato | Leerink Partners | Outperform |
| 2025-12-01 | Iniziato | Morgan Stanley | Overweight |
| 2025-12-01 | Iniziato | William Blair | Outperform |
Mostra tutto
Evommune Inc Borsa (EVMN) Ultime notizie
Assessing Evommune (EVMN) Valuation After Strong Phase 2a Eczema Data And US$125.3m Placement - Yahoo Finance
Evommune, Inc. (NYSE:EVMN) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism? - MSN
Evommune raises $125 million in private placement to fund R&D By Investing.com - Investing.com Nigeria
Evommune (NYSE:EVMN) Shares Gap UpHere's Why - MarketBeat
Weekly Buzz:FDA Okays NVCR's Cancer Device; RGNX Gets CRL;ONCO To Buy XBOT; PHIO's PH-762 Sets Pace - RTTNews
Evommune Inc on Feb 12, enters securities purchase agreement with investors - marketscreener.com
Evommune Announces $125 Million Private Placement Financing - TipRanks
Evommune Inc On Feb 12, Enters Securities Purchase Agreement With Investors - TradingView
Evommune Signs Multiple Material Agreements - TradingView
Evommune raises $125M privately - MSN
Evommune to Raise $125 Million Via Private Placement - marketscreener.com
Evommune's stock surges on strong results for new eczema drug - MSN
Evommune Secures $125M in Private Placement Agreement - Intellectia AI
Evommune’s atopic dermatitis drug meets primary endpoint in phase 2a trial - Investing.com Nigeria
Evommune Announces $125 Million Private Placement - Business Wire
Evommune Enters Private Placement Agreement for $125 Million - Intellectia AI
Evommune Stock Cools Off After Big Rally On Successful Eczema Trial - Bitget
Evommune (EVMN) Valuation Check After Positive Phase 2a EVO301 Results In Atopic Dermatitis - simplywall.st
Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill - BioPharma Dive
Evommune's EVO301 Phase 2a Data Drives 70% Stock Surge (NYSE:EVMN) - Seeking Alpha
Evommune’s stock rallies 70% on Phase IIa eczema data - Yahoo Finance
Biopharma companies Evommune and Nektar soar on eczema treatment data - Mugglehead Investment Magazine
Evommune stock price slips premarket after 71% jump on eczema drug data - Bez Kabli
Evommune’s atopic dermatitis drug meets primary endpoint in phase 2a trial By Investing.com - Investing.com South Africa
Evommune soars on mid-stage atopic dermatitis data - FirstWord Pharma
Evommune, Nektar assets join list of recent successes in atopic derm - biocentury.com
H.C. Wainwright maintains Buy for EVMN Evommune Inc Feb 10 2026 - Meyka
Evommune, Nektar soar on atopic dermatitis phase II data - BioWorld MedTech
Evommune’s Atopic Dermatitis Data Competitive With Dupixent - Citeline News & Insights
Health Care Stocks Split As Evommune Pops On Eczema Data - Finimize
Evommune Starts Making Case to Challenge Dominance of Sanofi’s Dupixent in Atopic Dermatitis - MedCity News
EVMN Stock Rating: Analyst Mitchell S. Kapoor Raises Price Targe - GuruFocus
Evommune stock price target raised to $55 by Evercore ISI on positive trial data By Investing.com - Investing.com India
Evommune stock price target raised to $55 by Evercore ISI on positive trial data - Investing.com
Evommune (NYSE:EVMN) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Evommune (NYSE:EVMN) Sets New 1-Year HighHere's What Happened - MarketBeat
Why Is Evommune Stock Soaring Today?Evommune (NYSE:EVMN) - Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Evommune Stock Soars 51% Over Positive Top-Line Data From Atopic Dermatitis Study - Nasdaq
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate - pharmiweb.com
Evommune Soars as Dermatitis Treatment Rivals Dupixent in Mid-Stage Trial - BioSpace
Evommune Says Atopic Dermatitis Treatment Achieved 'Statistically Significant' Outcomes in Proof-of-Concept Trial; Shares Rise - marketscreener.com
Evommune wins in mid-stage trial for eczema drug (EVMN:NYSE) - Seeking Alpha
Evommune reports positive mid-stage data for eczema drug - statnews.com
EVMN: EVO301 achieved significant efficacy and safety in Phase 2a atopic dermatitis trial - TradingView
Evommune's Dupixent-like eczema data drive 75% stock rally - Fierce Biotech
Evommune Advances EVO301 After Positive Phase 2a Results - TipRanks
Evommune, Inc. Announces Positive Phase 2a Trial Results for EVO301 in Atopic Dermatitis - TradingView
Evommune stock soars after positive Phase 2a trial results for eczema drug - Investing.com
Evommune reports EVO301 trial met primary endpoint - TipRanks
Evommune Inc Azioni (EVMN) Dati Finanziari
Non sono disponibili dati finanziari per Evommune Inc (EVMN). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):